Only 4.2% of participants discontinued due to side effects after week 24, indicating that side effects become manageable or resolve entirely for the vast majority who continue treatment
Chronic kidney disease affects 37 million Americans, with stages 1-2 showing minimal symptoms while stages 4-5 require dialysis preparation as kidney function drops below 30%
DSIP can often be safely combined with other sleep wellness approaches including cognitive behavioral therapy for insomnia (CBT-I), sleep hygiene optimization, other recovery-supporting peptides, magnesium and sleep-supporting supplements, melatonin (under medical guidance), adaptogenic herbs, and comprehensive sleep optimization protocols when properly coordinated under medical supervision
Products described here are supplied for research use only and are not intended for diagnostic, therapeutic, or clinical application
(a) MRI on advanced aged control (CTL) and transgenic (tauNFT) mice revealed abnormal ventricles, cerebral blood flow (CBF) and white matter hyperintensity (WMH) pathologies that were mitigated by (b) treatment with DQ
